HomeAI · summaries
Storia in 3 fonti
Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett Company
Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic move, expected to conclude by June 2026, will bolster Aurobindo's complex generics and controlled substances portfolio, enhance its US manufacturing capabilities with Lannett's Indiana facility, and is projected to immediately boost earnings per share.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett Company
Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic move, expected to conclude by June…
- ·
thehindubusinessline.com
Aurobindo Pharma gets US FTC’s nod to acquire Lannett Company
Aurobindo Pharma’s US subsidiary receives US FTC approval to acquire Lannett Company for $250 million, strengthening its position in non-opioid controlled substances and domestic…
- ·
thehindu.com
Aurobindo Pharma gets U.S. FTC go-ahead to acquire Lannett Company
Aurobindo Pharma secures FTC approval for a $250 million acquisition of Lannett Company, enhancing its U.S. manufacturing capabilities.